Orchid Pharma Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Orchid Pharma (NSE: ORCHPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Orchid Pharma trading at Rs 680 — against a 52-week high of Rs 1,100 and a 1-year return of -32% — the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector.

Analyst estimates for Q4 FY26 revenue stand at Rs 220–250 Cr, with PAT expectations of Rs 18–26 Cr and margin projections of EBITDA 14–18%. This article covers the Orchid Pharma Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Get free investment predictions and live Q4 result alerts on Univest.

Orchid Pharma Q4 Results 2026 Date

Orchid Pharma has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet on this date to approve the audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 680, investors will closely watch this announcement for guidance on revenue trajectory and margin outlook for FY27.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Orchid Pharma, operating in the Pharma sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management’s strategic initiatives are translating into financial results.

At a 1-year return of -32%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can recover to its 52-week high of Rs 1,100. Investors will focus on order book updates, margin trajectory, and capex plans — positive surprises on multiple parameters could drive meaningful re-rating.

Orchid Pharma Q4 FY26 Earnings Estimates

Orchid Pharma Q4 FY26 Analyst Estimates at a Glance | Source: MOFSL, YES Securities, JM Financial

Access premium SEBI-registered research on Univest.

Analysts covering Orchid Pharma have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 220–250 Cr, PAT of Rs 18–26 Cr, and margins of EBITDA 14–18%. These projections incorporate seasonal Q4 strength and ongoing business improvements.

Beyond headline numbers, investors will monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print — rather than one inflated by non-operational items — carries greater weight with long-term investors.

Screen Orchid Pharma fundamentals on Univest Screener.

5 Key Factors That Will Drive Orchid Pharma Q4 FY26 Performance

Revenue Growth Drivers in Pharma

Orchid Pharma’s Q4 FY26 revenue of Rs 220–250 Cr reflects sector-specific demand tailwinds and company-level execution. The Pharma segment is experiencing a recovery cycle driven by government policy support, consumer demand improvement, and post-pandemic normalisation. Orchid Pharma’s ability to capture this growth will depend on operational capacity, client relationships, and competitive positioning within its core markets.

Margin Recovery and Operating Leverage

Orchid Pharma’s Q4 FY26 margin estimate of EBITDA 14–18% reflects the expectation of improving operating leverage as revenues scale. Fixed cost absorption improves at higher revenue levels, and Q4’s seasonal strength is typically the most favourable quarter for margin improvement. Management’s cost discipline and pricing strategy will be key determinants of whether margins reach the upper end of analyst projections.

FY27 Guidance and Growth Visibility

Beyond Q4 FY26 numbers, the most consequential output from the results announcement will be FY27 guidance — revenue growth bands, margin targets, capex plans, and management commentary on macro environment. Orchid Pharma is at an inflection point where strong FY27 guidance could re-rate the stock significantly, given the current discount to its 52-week high.

Capital Allocation and Balance Sheet Quality

Orchid Pharma’s balance sheet health — net debt levels, working capital efficiency, and free cash flow generation — will be scrutinised in Q4 FY26 results. Strong free cash flow generation and debt reduction progress would indicate a self-funding growth model, reducing equity dilution risk and improving investor confidence in long-term value creation.

Competitive Positioning and Market Share

Orchid Pharma’s Q4 FY26 performance will reveal its competitive positioning within the Pharma sector. Market share trends, client additions, and new product/service introductions in the quarter will inform investors about the company’s ability to sustain growth above industry averages and justify a premium over sectoral peers.

5 Risks to Watch in Orchid Pharma Q4 FY26

Macroeconomic Headwinds and Demand Slowdown

The US tariff announcement in April 2026 has created global macroeconomic uncertainty affecting investor sentiment across Indian equity markets. For Orchid Pharma, indirect impacts include FII outflows, demand softness in export markets, and elevated input costs if global commodity prices remain elevated. Any deterioration in macro conditions for FY27 would require analyst estimate cuts.

Input Cost and Supply Chain Risk

Orchid Pharma is exposed to input cost volatility through its supply chain. Raw material price increases, logistics disruptions, or supply shortages — whether domestic or global — could compress margins and delay revenue recognition. Management’s ability to pass through cost increases to customers is a key differentiator between margin recovery and margin disappointment in Q4 FY26.

Competitive Pressure and Pricing Risk

The Pharma sector is experiencing intensifying competition from both established players and new entrants. Pricing pressure from competitors could force Orchid Pharma to offer discounts or invest more in customer acquisition, both of which compress margins. Any market share loss to competitors in Q4 FY26 would be viewed negatively by analysts.

Regulatory and Compliance Risk

Changes in government policy, regulatory requirements, or compliance standards in the Pharma sector could increase costs or disrupt business operations. SEBI, GST, environmental, or sector-specific regulations represent ongoing compliance requirements that could generate unexpected liabilities.

FY27 Guidance Risk and Estimate Cuts

If Orchid Pharma’s FY27 guidance falls below Street expectations — even if Q4 FY26 numbers are in line — the stock could decline significantly. The market prices forward earnings, and any negative guidance revision would trigger analyst estimate cuts and multiple compression. Management’s credibility on guidance delivery is therefore as important as the Q4 numbers themselves.

Orchid Pharma Share Price and Analyst Ratings

Orchid Pharma Share Price & Analyst Ratings | Source: NSE/BSE, Broker Notes

Orchid Pharma is trading at Rs 680 as of early April 2026, against a 52-week high of Rs 1,100 and 52-week low of Rs 540. Market cap stands at Rs 2,600 Cr. The 1-year return of -32% reflects both sector headwinds and company-specific factors. Analyst price targets diverge based on views on recovery pace and FY27 earnings potential.

Download the Univest iOS App or Univest Android App to track Orchid Pharma’s live price and receive real-time Q4 result alerts.

Conclusion

Orchid Pharma Q4 FY26 results will reflect the ongoing cephalosporin API business turnaround. At Rs 680 — 38% below its 52-week high — the stock prices in significant execution risk. A PAT of Rs 22 Cr+ combined with new ANDA filing announcements would signal that the recovery story is on track. Debt reduction progress is equally important for improving investor confidence. Consult a SEBI-registered advisor before investing.

This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.

For more Q4 FY26 previews across IT, banking, auto, pharma, and cement sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Orchid Pharma Q4 results 2026 date?

Orchid Pharma Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements and consider a dividend recommendation for FY26.

What is the Orchid Pharma Q4 FY26 PAT estimate?

Analysts estimate Orchid Pharma Q4 FY26 net profit (PAT) in the range of Rs 18–26 Cr, based on revenue of Rs 220–250 Cr and margin of EBITDA 14–18%. Actual results may differ from consensus estimates.

What is Orchid Pharma’s share price ahead of Q4 results?

Orchid Pharma shares are trading at approximately Rs 680 as of early April 2026. The 52-week high is Rs 1,100 and 52-week low is Rs 540. The one-year return is -32% and market cap stands at Rs 2,600 Cr.

Will Orchid Pharma declare a dividend in Q4 2026?

Orchid Pharma is expected to consider a dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected). This signals management’s confidence in FY26 free cash flow generation.

Which analysts have a Buy rating on Orchid Pharma?

MOFSL (target Rs 850), YES Securities (target Rs 900) have positive ratings on Orchid Pharma ahead of Q4 FY26 results.

What were Orchid Pharma Q3 FY26 results?

In Q3 FY26, Orchid Pharma reported revenue of Rs 198 Cr and PAT of Rs 14 Cr, with margins at EBITDA 15.2%. These provided the base for Q4 FY26 analyst estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026 — see the full TCS Q4 Results 2026 preview. Infosys announced Q4 FY26 results on April 23, 2026.

Is Orchid Pharma a good investment ahead of Q4 results?

Orchid Pharma at Rs 680 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates and consult a SEBI-registered advisor before making investment decisions.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Moschip Technologies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook